Document is current
Any future updates will be listed below
-
Authors
Raghavan, Rumya
Friedrich, Mirco J.
King, Indigo https://orcid.org/0009-0003-3048-4763
Chau-Duy-Tam Vo, Samuel https://orcid.org/0000-0001-6020-4716
Strebinger, Daniel https://orcid.org/0000-0001-8732-6414
Lash, Blake https://orcid.org/0000-0003-2445-7948
Kilian, Michael https://orcid.org/0000-0002-1946-3174
Platten, Michael https://orcid.org/0000-0002-4746-887X
Macrae, Rhiannon K. https://orcid.org/0000-0002-7850-9056
Song, Yifan
Nivon, Lucas
Zhang, Feng https://orcid.org/0000-0003-0178-7995
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
Poitras Center for Psychiatric Disorders Research at MIT; the Hock E. Tan and K. Lisa Yang Center for Autism Research at MIT; and the K. Lisa Yang and Hock E. Tan Molecular Therapeutics Center at MIT
- License Information
-
More Information
Article History
Received: 7 August 2024
Accepted: 16 December 2024
First Online: 2 January 2025
Competing interests
: F.Z., R.R., R.K.M., Y.S., L.N., and I.K. are co-inventors on a patent (“ENGINEERED TYPE II CAS POLYNUCLEOTIDES WITH REDUCED IMMUNOGENICITY AND USES THEREOF” (PCT/US2024/022898)) related to this work filed by the Broad Institute, MIT, and Cyrus Biotechnology. L.N. and Y.S. are executives at and co-founders of, and I.K. a senior scientist at, Cyrus Biotechnology. F.Z. is a scientific advisor and cofounder of Editas Medicine, Beam Therapeutics, Pairwise Plants, Arbor Biotechnologies, Aera Therapeutics, and Moonwalk Biosciences. F.Z. is a scientific advisor for Octant. M.J.F. reports speaker honoraria from Pfizer, Roche, and Kerna Ventures. The remaining authors declare no competing interests.
